- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Botox can safely prolong bladder enlargement time in some "at-risk" patients: study
Onabotulinum toxin A (BTX) can safely prolong bladder enlargement time in some "at-risk" patients, according to the latest research published in Neurourology and Urodynamics.
Augmentation Cystoplasty (Bladder Augmentation) The bladder is the organ that holds the urine. Augmentation cystoplasty, also known as bladder augmentation, is an operation to enlarge the bladder. This surgery may be necessary for people who have trouble urinating due to certain conditions.
Delaying bladder augmentation (BA) may be desirable in a pediatric neurogenic bladder (NGB) with worsening compliance, but previous studies have questioned whether onabotulinum toxin A (BTX) shows a lasting improvement in compliance. A group of researchers presents our overall experience with BTX and its role in reducing 'at-risk' NGB as determined by urodynamic properties.
A retrospective single-institution review of all BTX procedures performed between January 2010 and October 2018 was conducted. Patients with <12 months follow-up after the first BTX injection were excluded. The National Spina Bifida Patient Registry (NSBPR), as well as urodynamic studies (UDS), were reviewed to assign institutionally developed (LCH) risk stratification groups. Patients were considered "at-risk" for bladder enlargement if they had any of the following: moderate or hostile NSBPR risk grade; LCH risk grades indicating end-fill pressure >25 cmH2O or detrusor sphincter dyssynergia (DSD); upper system changes, including new hydronephrosis; new or worsening vesicoureteral reflux; or other manifestations of a hostile urinary tract (i.e., febrile UTI). Whenever possible, UDS risk ratings were compared before and after the first BTX injection in this "at-risk" group.
Results of the study:
• Thirty-nine patients underwent 162 injection procedures during a median follow-up of 65 months between quartiles.
• The median age at first BTX was ten years, the median number of BTX injections per patient was 4, and the median time between injections was six months.
• Twenty-six patients were considered 'at risk' at the time of the first BTX injection, and 16 (61.5%) of these progressed to bladder augmentation at a median of 36 months.
• Few (four) had bladder augmentation due to upper duct changes or worsening pressures on BTX, while nine patients (five with CKD) continued bladder augmentation because there was the insufficient improvement to consider BTX as a viable long-term option.
• Post-first BTX UDS showed a downgrade of the risk group by 38% and 63% using NSBPR and LCH classifications, respectively.
Thus, the researchers concluded that encouraging improvements were noted in the urodynamic risk group in some patients. With careful counselling and follow-up, BTX can safely prolong bladder enlargement time in some "at risk" patients.
Reference:
Bowen, DK, Meyer, T, Rosoklija, I, et al. Botulinum toxin in patients at-risk for bladder augmentation: durable impact or kicking the can? Neurourol Urodyn. 2022; 1- 8. doi:10.1002/nau.24962
Dr. Shravani Dali has completed her BDS from Pravara institute of medical sciences, loni. Following which she extensively worked in the healthcare sector for 2+ years. She has been actively involved in writing blogs in field of health and wellness. Currently she is pursuing her Masters of public health-health administration from Tata institute of social sciences. She can be contacted at editorial@medicaldialogues.in.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751